Lee Kalowski is recorded as CFO at Q32 Bio Inc. (QTTB) since March 25, 2024. The newest filing on record that lists Lee Kalowski as CFO at Q32 Bio Inc. (QTTB) is dated April 30, 2026. Earlier roles on record: CFO at Bicycle Therapeutics PLC (BCYC) until June 22, 2023. Q32 Bio Inc. reported in an 8-K filed March 27, 2024 that Lee Kalowski was appointed Chief Financial Officer and President, effective March 25, 2024. Bicycle Therapeutics PLC reported in an 8-K filed June 23, 2023 that Lee Kalowski resigned as Chief Financial Officer, effective June 22, 2023. The proxy statement of Q32 Bio Inc. reports total compensation of $987,147 for Lee Kalowski in fiscal 2025, including a base salary of $565,000. Disclosed compensation is on record for 4 fiscal years. Lee Kalowski has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Q32 Bio Inc. on September 15, 2026. Q32 Bio Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Q32 Bio Inc. includes Albert Seymour, Ph.D. (CEO and Board Member), Jodie Morrison (CEO and Board Member), Paul G. Alloway, Ph.D. (CEO and COO) and 7 others.
“On March 25, 2024, the Board appointed Jodie Morrison as our Chief Executive Officer and principal executive officer, Lee Kalowski as our Chief Financial Officer and President and principal financial officer and principal accounting officer, Jason Campagna as our Chief Medical Officer, and Shelia Violette as our Chief Scientific Officer and President of Research.”
Q32 Bio Inc. Form 8-K, filed March 27, 2024
· Read the filing
“Ms. Young will replace Lee Kalowski, who has resigned from his role as Chief Financial Officer and all other roles he holds with the Company and Bicycle Therapeutics Inc. ("BTI"), effective as of June 22, 2023 (the "Transition Date").”
Bicycle Therapeutics PLC Form 8-K, filed June 23, 2023
· Read the filing
Lee Kalowski on recent calls
“It's one that we get asked a fair amount. And I think, generally speaking, there's an underappreciation of how many patients are out there desperate for new treatment and new alternatives, and thus commercially how substantial the market opportunity is.”
“Before we begin, I would like to remind you of the disclaimer outlined on slide two. During today's presentation, including during the question and answer portion of the call, we will be making certain forward-looking statements.”
